(Total Views: 504)
Posted On: 10/20/2017 10:22:47 PM
Post# of 15624
I feel this has been severely overlooked, it's from an April 4th 8-k. It clearly states the safety study had begun, and also states there plan for the future of it. Here it is, and is probably why the safety trial is taken longer then some would like.
A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease. The study is carefully managed by Dr. Yehuda Baruch, the Company's CSO & Director of Research and Regulatory Affairs. Dr. Baruch comments, "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments".
A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease. The study is carefully managed by Dr. Yehuda Baruch, the Company's CSO & Director of Research and Regulatory Affairs. Dr. Baruch comments, "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments".
(1)
(0)Scroll down for more posts ▼
